Friedreich’s ataxia (FA) is a rare, autosomal recessive neurodegenerative disease whose natural history and clinical characterization have made significant progress in recent decades. Nevertheless, there is still a lack of sensitive, objective biomarkers that both reliably reflect disease progression and are practicable for clinical studies. The TRACK-FA study, the largest multicenter, multimodal neuroimaging study in FA to date, is now making a decisive contribution. It shows that structural and functional imaging markers not only detect disease-relevant changes, but also correlate with clinical scales. This opens up new avenues for more precise diagnostics, the development of therapies and the shortening of study durations.
Autoren
- Tanja Schliebe
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- Diabetes mellitus
Treatment of comorbidities in older people
- Alternative to insulin and GLP1
From the β-cell to the center: the versatile role of amylin
- Pulmonary sarcoidosis
Prednisone vs. MTX: a draw after 24 weeks
- Friedreich's ataxia
Loss of orientation in the cerebellum
- Diabetes mellitus
Treatment of comorbidities in older people
- Artificial intelligence
Dr. ChatGPT: Large language models in everyday clinical practice
- Subtyping as the key to precision medicine
Molecular diversity of the PDAC
- Multiple sclerosis